-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Cigarette Sales Up in U.S. for the First Time in 20 Years
October 26, 2021—The U.S. Federal Trade Commission’s (FTC’s) recently released Cigarette Report1 showed that the number of cigarettes sold increased from 202.9 billion in 2019 to 203.7 billion in 2020. This was the first increase in cigarette sales in 20 years in the United States. Advertising expenditures also increased during the same time period, from…
-
Intratumoral Dendritic Cells in Treatment of Lung Cancer
In the past decade, targeting of the PD-1/PD-L1 checkpoint, with or without CTLA-4 targeting, has revolutionized cancer treatment. However, a significant proportion of patients with lung cancer still do not benefit from these advances. In the patients who benefit most, the expression of PD-L1 in the tumor is, in general, high.1 An effective immune response…
-
Studies Question Further Modification of pTNM Staging as 9th Edition Deadline Approaches
Two studies presented at the WCLC Congress 2021 include data that suggest the potential need to update the current TNM classification of lung cancers by implementing additional pathological elements to the evaluation of the specimen. Commenting on these two studies, Jorge Alatorre-Alexander, MD, of Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, admitted that reclassifying…
-
New Warranty, Rebate Programs Put Spotlight on Value in Lung Cancer
Value-based care is getting more attention in lung cancer thanks to two new programs offering significant rebates or full refunds should the therapeutic agent be ineffective or intolerable. Pfizer’s pilot project, a U.S.-based program that runs through the end of the year, covers the cost of Xalkori (crizotinib) paid by the patient, Medicare, or private…
-
Rare NUT Carcinoma Gaining Recognition in Lung Cancer Community
In 2015, the World Health Organization (WHO) revised its 2004 classification of lung tumors to reflect the impact of genetic, clinical, and radiologic advances in the field.1 Among the revisions in 2015 was the inclusion of NUT carcinoma. “NUT carcinoma is a very rare and highly lethal cancer. It often presents in the midline and…
-
Benefit to Pembrolizumab Observed in Previously Treated Malignant Pleural Mesothelioma Irrespective of PD-L1 Status
Treatment options for patients with malignant pleural mesothelioma (MPM) are limited. While patients with advanced or inoperable MPM are traditionally treated with cisplatin and pemetrexed as a standard first-line treatment, there is still no established standard-of-care second-line therapy for these patients.1 Current second-line options after platinum-based chemotherapy have typically included either immune checkpoint inhibitors or…
-
Assay that Combines Clinical, Radiomic Characteristics with CT Information Shown to Better Distinguish Malignant Early Lung Nodules
Although low-dose CT scans enable the detection of very small lung nodules in individuals who face a high risk of developing lung cancer, it is often impossible to quickly determine whether the lesions are malignant due to their size or location. Technology designed to enhance the depth of information available when reading a CT scan…
-
Comprehensive Analysis of Proteomics Identifies New, Druggable Drivers of NSCLC—and New Avenue for Continued Research
Despite the past decade’s accomplishments in identifying the genetic drivers of NSCLC, the complexity of these cancers continues to create barriers to effective targeted treatment. Finding strategies capable of overcoming those barriers will depend, in part, on the in-depth study of the proteins whose activity causes oncogenicity, according to Ramaswamy Govindan, MD, a medical oncologist…
-
Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%
October 15, 2021— Based on the results of phase III IMpower010, atezolizumab was approved by the U.S. Food and Drug Administration (FDA) as adjuvant treatment after surgery and chemotherapy for patients with stage II-IIIA NSCLC and with a PD-L1 expression level of ≥ 1%. The VENTANA PD-L1 (SP263) Assay also was approved as a companion…
-
Toward More Inclusive, Accessible Clinical Trial Consent Forms
It is a trend many years in the making, but the time is ripe to fix the increasing problems with clinical trial consent documentation. The word count and complexity of mandated information in informed consent forms have been multiplying, but their value remains dubious. In 2016, Danish researchers studying consent forms found that “a considerable…
View ILCN Archives
Provider Resources
Popular Articles